Program Description
The high cost of biologic oncology drugs continues to place significant burden on both patients and the healthcare system. Biosimilars have been developed as alternatives to biologics, with trials proving no meaningful differences in safety, purity, or potency. In recent years, the technologies involved in the development of biosimilars have driven improvements in access to care and treatment while reducing overall healthcare costs. As more biosimilars become available and enter the market, managed care pharmacists must weigh several factors, including the impact of national and state laws, manufacturing considerations, and the potential for improved value-based care stemming from the incorporation of biosimilars into clinical practice. This article will discuss current perspectives and barriers influencing the adoption of oncology biosimilars for formulary inclusion as well as strategies managed care pharmacists can implement to promote the uptake of biosimilars in clinical practice, especially for the treatment of cancer.
Target audience: Managed care pharmacists, oncology pharmacists
Type of activity: Application
Release date: June 29, 2022
Expiration date: June 29, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Determine potential economic benefits associated with oncology biosimilars in reducing overall cost of care for patients with cancer.
- Explain the factors considered when evaluating biosimilars for inclusion into formularies and clinical pathways.
- Identify opportunities for improvements in value of care associated with implementation of oncology biosimilars in clinical practice.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
